Pivotal Treatment in Breast Cancer Education Center
Approximately 20% of patients diagnosed with breast cancer have a type of cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein. HER2 positive breast cancers are unique due to the significant efficacy of treatments that target the HER2 protein. Furthermore, treatments for HER2 positive breast cancer are effective for both patients with early stage and metastatic breast cancer. Recent advances in the treatment of HER positive breast cancer continue to dramatically improve outcomes for these patients.
This Education Center is intended to update clinicians on the latest developments in HER positive breast cancer in order to help them more effectively treat patients.